Literature DB >> 30368724

Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with 125I seeds intracavitary irradiation.

X Hu1, Q Pang2, H Liu3, Z Qian1, H Jin1, L Zhou1, Y Wang1, Z Man1, Z Li1, S Yang1.   

Abstract

PURPOSE: This study aimed at investigating the efficacy of percutaneous transhepatic biliary stenting (PTBS) combined with 125I seeds intracavitary irradiation in the treatment of extrahepatic cholangiocarcinoma (EHC) and to preliminarily explore the prognostic values of inflammation-based scores in these patients.
METHODS: A total of 113 clinically/pathologically diagnosed cases of EHC who received PTBS combined with 125I seeds implantation were retrospectively analyzed. The postoperative changes of clinical symptoms and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total serum bilirubin (TBIL), direct bilirubin (DBIL), and albumin (ALB) were observed. Preoperative clinical data were extracted to calculate inflammation-based scores, including systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelets-to-lymphocyte ratio (PLR). Kaplan-Meier survival curves and Cox regression analyses were used to evaluate the prognostic significance of inflammation-based scores.
RESULTS: After operation, clinical symptoms such as jaundice and fever significantly improved in all patients. At 1 month and 3 months postoperatively, serum levels of ALT, AST, ALP, TBIL, and DBIL significantly reduced, and ALB significantly increased, compared with preoperative values. The median survival time of the patients was 12 months and the 1-year survival rate was 56.8%. Univariate analysis revealed that factors related to overall survival were CA19-9, TBIL, ALB, SII, and NLR. Multivariate analysis further identified SII and NLR as independent prognostic models.
CONCLUSION: The combination of PTBS and 125I seeds intracavitary irradiation is an effective palliative treatment for advanced EHC. Elevated SII and NLR can be used to predict poor survival.

Entities:  

Keywords:  125I seeds; Biliary stenting; Extrahepatic cholangiocarcinoma; Neutrophil-to-lymphocyte ratio; Systemic immune-inflammation index

Mesh:

Substances:

Year:  2018        PMID: 30368724     DOI: 10.1007/s12094-018-1969-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  45 in total

1.  Percutaneous biliary metal wall stenting in malignant obstructive jaundice.

Authors:  Adrian A Indar; Dileep N Lobo; Andrew D Gilliam; Roger Gregson; Ian Davidson; Simon Whittaker; John Doran; Brian J Rowlands; Ian J Beckingham
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 2.566

2.  PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

Authors:  Feng Shi; Ming Shi; Zhen Zeng; Rui-Zhao Qi; Zhen-Wen Liu; Ji-Yuan Zhang; Yong-Ping Yang; Po Tien; Fu-Sheng Wang
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent.

Authors:  Hai-Dong Zhu; Jin-He Guo; Guang-Yu Zhu; Shi-Cheng He; Wen Fang; Gang Deng; Yong-Lin Qin; Guo-Zhao Li; Douglas M Coldwell; Gao-Jun Teng
Journal:  J Hepatol       Date:  2012-01-17       Impact factor: 25.083

4.  Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy.

Authors:  Subir Nag; Megan DeHaan; Granger Scruggs; Nina Mayr; Edward W Martin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-07       Impact factor: 7.038

5.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

6.  Brachytherapy in the treatment of cholangiocarcinoma.

Authors:  Eric T Shinohara; Mengye Guo; Nandita Mitra; James M Metz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-06       Impact factor: 7.038

7.  C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma.

Authors:  Thomas Gerhardt; Sabine Milz; Michael Schepke; Georg Feldmann; Martin Wolff; Tilman Sauerbruch; Franz Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

8.  Dosimetric characteristics of the Pharma Seed model BT-125-I source.

Authors:  C C Popescu; J Wise; K Sowards; A S Meigooni; G S Ibbott
Journal:  Med Phys       Date:  2000-09       Impact factor: 4.071

9.  Guidelines for palliative surgery of cholangiocarcinoma.

Authors:  H Witzigmann; H Lang; H Lauer
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 10.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

View more
  1 in total

1.  Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients.

Authors:  Buwen Zhang; Weiyun Yao
Journal:  World J Surg Oncol       Date:  2022-09-29       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.